Matches in SemOpenAlex for { <https://semopenalex.org/work/W2109218307> ?p ?o ?g. }
Showing items 1 to 92 of
92
with 100 items per page.
- W2109218307 endingPage "61" @default.
- W2109218307 startingPage "2755" @default.
- W2109218307 abstract "Capecitabine (Xeloda) is a novel rationally designed fluoropyrimidine carbamate. It passes through the intestinal mucosal membrane intact and is subsequently activated by a cascade of three enzymes resulting in preferential release of 5-fluorouracil (5-FU) at the tumor site. Preclinical studies indicated an enhancement of the therapeutic index when capecitabine was combined with leucovorin. This Phase I trial was designed to determine the safety profile, maximal tolerated dose, and pharmacokinetic profile of the combination of capecitabine plus a fixed dose of p.o. leucovorin (60 mg/day) during administration to patients with refractory advanced cancers. The intention was to administer both drugs continuously, but the starting dose of capecitabine was also the maximum tolerated dose (1004 mg/m2/day) in six patients treated with this regimen. A cycle of treatment was then redefined as leucovorin and capecitabine given p.o., twice daily for 2 consecutive weeks followed by a 1-week rest period. Capecitabine doses from 1004 mg/m2/day to 2510 mg/m2/day were evaluated with the intermittent schedule over approximately 80 courses in an additional 25 patients. The dose-limiting toxicities that defined the maximum tolerated dose at 2000 mg/m2/day were diarrhea, nausea, vomiting, and palmar plantar erythrodysesthesia. The recommended Phase II dose using this schedule was 1650 mg/m2/day of capecitabine plus leucovorin 60 mg/day. Plasma concentrations of capecitabine, intermediate metabolites, and 5-FU were measured in 26 patients on days 1 and 14 of therapy. The pharmacokinetics of capecitabine were characterized by rapid GI absorption, with Cmax at 1 h, followed by conversion to active drug. The coadministration of leucovorin had no effect on the pharmacokinetics of capecitabine. Two patients with colorectal cancer, both previously treated with 5-FU, had partial responses. Phase II studies have confirmed the promising antitumor activity of this drug, and capecitabine is currently in Phase III evaluation." @default.
- W2109218307 created "2016-06-24" @default.
- W2109218307 creator A5007926068 @default.
- W2109218307 creator A5015426297 @default.
- W2109218307 creator A5016595873 @default.
- W2109218307 creator A5017808412 @default.
- W2109218307 creator A5022173747 @default.
- W2109218307 creator A5024897875 @default.
- W2109218307 creator A5042403751 @default.
- W2109218307 creator A5057956386 @default.
- W2109218307 date "1998-11-01" @default.
- W2109218307 modified "2023-09-29" @default.
- W2109218307 title "A Phase I study of capecitabine in combination with oral leucovorin in patients with intractable solid tumors." @default.
- W2109218307 cites W1571748472 @default.
- W2109218307 cites W1773171357 @default.
- W2109218307 cites W1844072307 @default.
- W2109218307 cites W1847455118 @default.
- W2109218307 cites W1888050314 @default.
- W2109218307 cites W1950204311 @default.
- W2109218307 cites W1979110171 @default.
- W2109218307 cites W2030395635 @default.
- W2109218307 cites W2089459595 @default.
- W2109218307 cites W2113550611 @default.
- W2109218307 cites W2117206082 @default.
- W2109218307 cites W2155421004 @default.
- W2109218307 cites W2156496879 @default.
- W2109218307 cites W2396646859 @default.
- W2109218307 cites W2409031629 @default.
- W2109218307 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9829739" @default.
- W2109218307 hasPublicationYear "1998" @default.
- W2109218307 type Work @default.
- W2109218307 sameAs 2109218307 @default.
- W2109218307 citedByCount "35" @default.
- W2109218307 countsByYear W21092183072012 @default.
- W2109218307 countsByYear W21092183072017 @default.
- W2109218307 countsByYear W21092183072018 @default.
- W2109218307 crossrefType "journal-article" @default.
- W2109218307 hasAuthorship W2109218307A5007926068 @default.
- W2109218307 hasAuthorship W2109218307A5015426297 @default.
- W2109218307 hasAuthorship W2109218307A5016595873 @default.
- W2109218307 hasAuthorship W2109218307A5017808412 @default.
- W2109218307 hasAuthorship W2109218307A5022173747 @default.
- W2109218307 hasAuthorship W2109218307A5024897875 @default.
- W2109218307 hasAuthorship W2109218307A5042403751 @default.
- W2109218307 hasAuthorship W2109218307A5057956386 @default.
- W2109218307 hasConcept C112705442 @default.
- W2109218307 hasConcept C121608353 @default.
- W2109218307 hasConcept C126322002 @default.
- W2109218307 hasConcept C2776694085 @default.
- W2109218307 hasConcept C2777909004 @default.
- W2109218307 hasConcept C2780456651 @default.
- W2109218307 hasConcept C2780580376 @default.
- W2109218307 hasConcept C2780852908 @default.
- W2109218307 hasConcept C2781413609 @default.
- W2109218307 hasConcept C526805850 @default.
- W2109218307 hasConcept C71924100 @default.
- W2109218307 hasConcept C90924648 @default.
- W2109218307 hasConcept C98274493 @default.
- W2109218307 hasConceptScore W2109218307C112705442 @default.
- W2109218307 hasConceptScore W2109218307C121608353 @default.
- W2109218307 hasConceptScore W2109218307C126322002 @default.
- W2109218307 hasConceptScore W2109218307C2776694085 @default.
- W2109218307 hasConceptScore W2109218307C2777909004 @default.
- W2109218307 hasConceptScore W2109218307C2780456651 @default.
- W2109218307 hasConceptScore W2109218307C2780580376 @default.
- W2109218307 hasConceptScore W2109218307C2780852908 @default.
- W2109218307 hasConceptScore W2109218307C2781413609 @default.
- W2109218307 hasConceptScore W2109218307C526805850 @default.
- W2109218307 hasConceptScore W2109218307C71924100 @default.
- W2109218307 hasConceptScore W2109218307C90924648 @default.
- W2109218307 hasConceptScore W2109218307C98274493 @default.
- W2109218307 hasIssue "11" @default.
- W2109218307 hasLocation W21092183071 @default.
- W2109218307 hasOpenAccess W2109218307 @default.
- W2109218307 hasPrimaryLocation W21092183071 @default.
- W2109218307 hasRelatedWork W2072252734 @default.
- W2109218307 hasRelatedWork W2091590120 @default.
- W2109218307 hasRelatedWork W2137086876 @default.
- W2109218307 hasRelatedWork W2244266286 @default.
- W2109218307 hasRelatedWork W2350882234 @default.
- W2109218307 hasRelatedWork W2363692413 @default.
- W2109218307 hasRelatedWork W2364816840 @default.
- W2109218307 hasRelatedWork W2371226160 @default.
- W2109218307 hasRelatedWork W2468000090 @default.
- W2109218307 hasRelatedWork W2472155679 @default.
- W2109218307 hasVolume "4" @default.
- W2109218307 isParatext "false" @default.
- W2109218307 isRetracted "false" @default.
- W2109218307 magId "2109218307" @default.
- W2109218307 workType "article" @default.